- Ulcerative colitis (UC) is part of the inflammatory bowels diseases, and moderate to severe UC patients can be treated with anti-tumour necrosis alpha monoclonal antibodies, including infliximab (IFX). Even though treatment of UC patients by IFX has been in place for over a decade, many gaps in modelling of IFX PK in this population remain. This is even more true for acute severe UC (ASUC) patients for which early prediction of IFX pharmacokinetic (PK) could highly improve treatment outcome. Thus, this review aims to compile and analyse published population PK models of IFX in UC and ASUC patients, and to assess the current knowledge on disease activity impact on IFX PK. For this, a semi-systematic literature search was conducted, from which 26 publications including a population PK model analysis of UC patients receiving IFX therapy were selected. Amongst those, only four developed a model specifically for UC patients, and only three populations included severe UC patients. Investigations of disease activity impact on PK wereUlcerative colitis (UC) is part of the inflammatory bowels diseases, and moderate to severe UC patients can be treated with anti-tumour necrosis alpha monoclonal antibodies, including infliximab (IFX). Even though treatment of UC patients by IFX has been in place for over a decade, many gaps in modelling of IFX PK in this population remain. This is even more true for acute severe UC (ASUC) patients for which early prediction of IFX pharmacokinetic (PK) could highly improve treatment outcome. Thus, this review aims to compile and analyse published population PK models of IFX in UC and ASUC patients, and to assess the current knowledge on disease activity impact on IFX PK. For this, a semi-systematic literature search was conducted, from which 26 publications including a population PK model analysis of UC patients receiving IFX therapy were selected. Amongst those, only four developed a model specifically for UC patients, and only three populations included severe UC patients. Investigations of disease activity impact on PK were reported in only 4 of the 14 models selected. In addition, the lack of reported model codes and assessment of predictive performance make the use of published models in a clinical setting challenging. Thus, more comprehensive investigation of PK in UC and ASUC is needed as well as more adequate reports on developed models and their evaluation in order to apply them in a clinical setting.…
MetadatenAuthor details: | Alix DémarisORCiD, Ella S. K. Widigson, Johan F. K. F. Ilvemark, Casper SteenholdtORCiD, Jakob B. SeidelinORCiD, Wilhelm HuisingaORCiDGND, Robin MicheletORCiD, Linda B. S. AulinORCiD, Charlotte KloftORCiDGND |
---|
DOI: | https://doi.org/10.3390/pharmaceutics14102095 |
---|
ISSN: | 1999-4923 |
---|
Pubmed ID: | https://pubmed.ncbi.nlm.nih.gov/36297530 |
---|
Title of parent work (English): | Pharmaceutics / Molecular Diversity Preservation International |
---|
Subtitle (English): | results from a comprehensive review |
---|
Publisher: | MDPI |
---|
Place of publishing: | Basel |
---|
Publication type: | Article |
---|
Language: | English |
---|
Date of first publication: | 2022/09/30 |
---|
Publication year: | 2022 |
---|
Release date: | 2023/11/01 |
---|
Tag: | acute severe; disease activity; inflammatory bowel disease; infliximab; pharmacokinetic; pharmacometrics; ulcerative colitis |
---|
Volume: | 14 |
---|
Issue: | 10 |
---|
Article number: | 2095 |
---|
Number of pages: | 32 |
---|
Organizational units: | Mathematisch-Naturwissenschaftliche Fakultät / Institut für Mathematik |
---|
DDC classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
---|
Peer review: | Referiert |
---|
Publishing method: | Open Access / Gold Open-Access |
---|
| DOAJ gelistet |
---|
License (German): | CC-BY - Namensnennung 4.0 International |
---|